+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
C1-INH Replacement Therapy Market by Product Type (Plasma Derived C1-INH, Recombinant C1-INH), Indication (Acute Treatment, Prophylaxis), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
C1-INH Replacement Therapy Market by Product Type (Plasma Derived C1-INH, Recombinant C1-INH), Indication (Acute Treatment, Prophylaxis), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

C1-INH Replacement Therapy Market by Product Type (Plasma Derived C1-INH, Recombinant C1-INH), Indication (Acute Treatment, Prophylaxis), Route of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6117834
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
In recent years, the therapeutic sphere for hereditary angioedema and related disorders has undergone a profound transformation driven by advances in protein engineering, enhanced safety measures, and renewed emphasis on patient outcomes. The advent of specialized C1-Inhibitor replacement options has shifted treatment paradigms from acute intervention toward a more proactive, prevention-oriented model. Stakeholders spanning biopharmaceutical innovators, healthcare providers, and patient advocacy organizations are increasingly collaborating to refine dosing regimens, broaden access pathways, and align on best practices for long-term disease management.

Moreover, evolving regulatory landscapes across major healthcare regions have created both opportunities and complexities for manufacturers seeking to diversify their product portfolios. As a result, companies are investing in robust clinical evidence programs and developing both plasma-derived and recombinant variants to address distinct patient populations. This report opens by contextualizing the foundational science of C1-Inhibitor replacement therapies, highlights the progression of delivery modalities, and underscores the collaborative frameworks that are shaping tomorrow’s standard of care. By framing the current landscape with these insights, we prepare readers to navigate the detailed explorations that follow.

Unveiling Emerging Breakthroughs and Technology-Driven Disruptions Catalyzing the Evolution of C1-Inhibitor Replacement Therapeutic Landscape

The landscape of C1-Inhibitor replacement therapy has been redefined by an array of technological breakthroughs and novel therapeutic strategies, catalyzing a shift from traditional plasma concentrates toward sophisticated biotech constructs. Advances in nanofiltration techniques and precision pasteurization now deliver plasma-derived formulations with unparalleled levels of viral safety. Simultaneously, recombinant approaches are leveraging targeted protein expression systems to offer consistent product quality and reduced dependency on donor pools.

Concurrently, the rise of subcutaneous self-administration is challenging the historical dominance of intravenous infusions by offering patients greater autonomy, reduced healthcare resource utilization, and more predictable pharmacokinetic profiles. Transitioning from reactive acute management to long-term prophylaxis, developers are exploring optimized dosing schedules that can seamlessly integrate into patients’ daily routines. Taken together, these trends are fostering a more patient-centric paradigm, encouraging more proactive disease control and driving competitive differentiation through formulation innovation, digital support tools, and integrated care models.

Examining the Projected Impacts of Upcoming United States Tariff Policies on C1-Inhibitor Supply Chains and Competitive Dynamics

Anticipated adjustments to tariff structures by the United States in 2025 are poised to have multifaceted effects on the global supply chains underpinning C1-Inhibitor replacement therapies. Tighter duty regimes on imported raw materials could amplify costs for plasma collection centers and contract manufacturing organizations, prompting biopharmaceutical companies to reassess sourcing strategies and vertically integrate critical processing steps.

In response, industry leaders may accelerate investments in domestic purification infrastructure or explore alternative expression platforms that mitigate reliance on cross-border shipments. At the same time, potential shifts in duty classifications for recombinant expression systems could influence pricing negotiations and reimbursement discussions with payers. By closely monitoring these policy changes, stakeholders can preemptively align procurement frameworks, optimize inventory management, and safeguard patient access by distributing risk across diversified supply networks.

Deciphering Critical Segmentation Patterns Shaping C1-Inhibitor Replacement Markets Across Product Types, Indications, Administration and Channels

Understanding the multifaceted segmentation of the C1-Inhibitor replacement arena illuminates core product and patient demographics steering innovation and market uptake. Analysis of product classifications reveals a clear dichotomy between plasma-derived C1-Inhibitors, which include both nanofiltered and pasteurized variants, and recombinant products engineered through targeted cellular expression. Examining therapeutic indications highlights the distinction between acute attack management and prophylactic usage, with prophylaxis further divided into long-term regimens designed for consistent protection and short-term interventions aimed at perioperative or episodic risk mitigation.

Complementing these therapeutic and formulation segments, administration routes bifurcate into intravenous infusions traditionally administered in clinical settings and emergent subcutaneous applications that facilitate self-care. The end-user environment ranges from hospital and specialty clinic administrations to homecare delivery models that grant patients greater autonomy. Finally, distribution channels traverse hospital pharmacies, online platforms, and retail outlets, each presenting distinct logistical and reimbursement considerations. Integrating these segmentation facets reveals nuanced opportunities for differentiated positioning, tailored clinical development, and streamlined patient engagement.

Regional Outlook Reveals Strategic Growth Drivers and Patient Access Challenges for C1-Inhibitor Replacement Across Global Markets

Regional characteristics exert a powerful influence on the adoption and diffusion of C1-Inhibitor replacement therapies, reflecting variations in regulatory frameworks, healthcare infrastructure, and payer landscapes. In the Americas, established plasma fractionation networks and supportive reimbursement policies have facilitated broad patient access to both acute and prophylactic formulations. Collaborative networks between clinical centers and patient organizations further reinforce adherence initiatives and education programs.

Across Europe, Middle East, and Africa, multinational coordination of health technology assessments has given rise to more uniform reimbursement pathways, while regional centers of excellence foster specialized care delivery. However, country-specific regulatory requirements and centralized procurement practices continue to pose challenges to market entrants. In Asia-Pacific, heterogeneous economic environments and evolving healthcare reform efforts are driving initiatives to establish local manufacturing capabilities and public-private partnerships. This regional mosaic underscores the imperative for commercial strategies tailored to each jurisdiction’s policy drivers and patient access priorities.

Profiling Leading Innovators and Emerging Players Driving Competitive Advances in C1-Inhibitor Replacement Therapy Arena Globally

Leading multinational biopharmaceutical corporations are harnessing both legacy expertise in protein purification and novel bioprocess innovations to expand their C1-Inhibitor portfolios. Established players have fortified their competitive edge through incremental enhancements in viral safety processes, while bolstering patient support frameworks that streamline reimbursement and adherence. At the same time, midsize biotech pioneers are making inroads by focusing on recombinant expression platforms that promise more predictable supply and scalable capacity.

Emerging biotech companies are leveraging adaptive clinical trial designs to explore subcutaneous formulations and novel prophylactic dosing paradigms, thereby carving out differentiated niches. In parallel, specialized contract manufacturing organizations are investing in modular purification suites capable of rapidly switching between nanofiltration and pasteurization workflows. These combined efforts are intensifying competitive dynamics, compelling incumbents and new entrants alike to seek strategic alliances, co-development arrangements, and geographic expansion to reinforce their market positions.

Strategic Imperatives for Industry Stakeholders to Accelerate Adoption, Optimize Patient Outcomes and Strengthen Market Positioning in C1-Inhibitor

Industry stakeholders should prioritize seamless integration of patient-centric delivery models, expanding subcutaneous self-administration programs while reinforcing training and telehealth support to optimize outcomes. Building localized manufacturing alliances can mitigate supply chain vulnerabilities, particularly in the face of evolving trade policies. Moreover, developing flexible pricing frameworks aligned with payer expectations will be essential as reimbursement landscapes adapt to value-based care paradigms.

Biopharma companies must also invest in real-world evidence generation to demonstrate the longitudinal benefits of both prophylactic and acute regimens, thereby strengthening payer negotiations and expanding label indications. Cross-functional collaborations between medical affairs, commercial teams, and regulatory experts can accelerate market access pathways. Finally, leveraging digital health tools to monitor adherence, manage adverse events, and gather patient insights will create differentiated offerings that resonate with healthcare providers and patient communities alike.

Comprehensive Multi-Source Methodological Framework Underpinning the Rigorous Analysis of C1-Inhibitor Replacement Therapy Insights and Trends

This analysis is grounded in a rigorous, multi-source research framework that synthesizes both qualitative and quantitative insights. Secondary research included a comprehensive review of peer-reviewed publications, clinical trial registries, regulatory guidelines, and proprietary patent databases to map the scientific evolution of C1-Inhibitor therapies. Primary research efforts encompassed in-depth interviews with key opinion leaders spanning allergists, immunologists, hematologists, and patient advocacy representatives, ensuring a holistic understanding of clinical and real-world treatment dynamics.

Quantitative validation was achieved through targeted surveys with healthcare professionals and procurement specialists across multiple geographies, providing granular data on treatment utilization patterns and supply chain considerations. Finally, triangulation of findings from industry expert workshops, financial filings, and strategic investor presentations underpinned the robust conclusions and actionable recommendations detailed herein.

Synthesizing Key Takeaways to Guide Future Innovations, Policy Considerations and Collaborative Pathways in C1-Inhibitor Replacement Therapy Domain

Drawing together thematic threads from the preceding sections, the current landscape underscores a clear shift toward personalized, prophylactic management underpinned by both plasma-derived and recombinant technologies. Trade policy fluctuations in the United States heighten the importance of agile supply chain architectures, while segmentation analyses demonstrate the critical interplay between formulation attributes, administration routes, and distribution pathways.

Regional insights spotlight the necessity of adaptive market entry strategies across the Americas, EMEA, and Asia-Pacific, taking into account regulatory nuances and infrastructure maturity. Competitive profiling reveals that established manufacturers and innovative biotech entrants must continue investing in viral safety enhancements, digital support ecosystems, and real-world evidence to maintain differentiation. As a result, industry leaders equipped with the strategic imperatives outlined herein will be best positioned to navigate evolving patient needs, regulatory shifts, and collaborative frameworks that define the future of C1-Inhibitor replacement therapy.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Product Type
    • Plasma Derived C1-INH
      • Nanofiltered C1-INH
      • Pasteurized C1-INH
    • Recombinant C1-INH
  • Indication
    • Acute Treatment
    • Prophylaxis
      • Long Term Prophylaxis
      • Short Term Prophylaxis
  • Route Of Administration
    • Intravenous
    • Subcutaneous
  • End User
    • Homecare Setting
    • Hospital
    • Specialty Clinic
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Pharming Group N.V.
  • Swedish Orphan Biovitrum AB
  • Kedrion S.p.A.
  • LFB S.A.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of subcutaneous C1-INH administration protocols in hereditary angioedema prophylaxis
5.2. Emerging recombinant C1-INH therapies demonstrating extended half-life and improved pharmacokinetics to reduce infusion frequency
5.3. Growing focus on health economic outcomes and payer reimbursement models for long-term C1-INH therapy affordability
5.4. Increasing patient preference for home-based self-administration and digital monitoring solutions in C1-INH management
5.5. Expansion of C1-INH replacement therapy approval and commercialization in Asia-Pacific and Latin America markets
5.6. Competitive pressure from oral plasma kallikrein inhibitors influencing future C1-INH replacement therapy pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. C1-INH Replacement Therapy Market, by Product Type
8.1. Introduction
8.2. Plasma Derived C1-INH
8.2.1. Nanofiltered C1-INH
8.2.2. Pasteurized C1-INH
8.3. Recombinant C1-INH
9. C1-INH Replacement Therapy Market, by Indication
9.1. Introduction
9.2. Acute Treatment
9.3. Prophylaxis
9.3.1. Long Term Prophylaxis
9.3.2. Short Term Prophylaxis
10. C1-INH Replacement Therapy Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Subcutaneous
11. C1-INH Replacement Therapy Market, by End User
11.1. Introduction
11.2. Homecare Setting
11.3. Hospital
11.4. Specialty Clinic
12. C1-INH Replacement Therapy Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas C1-INH Replacement Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa C1-INH Replacement Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific C1-INH Replacement Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. Pharming Group N.V.
16.3.4. Swedish Orphan Biovitrum AB
16.3.5. Kedrion S.p.A.
16.3.6. LFB S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. C1-INH REPLACEMENT THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. C1-INH REPLACEMENT THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. C1-INH REPLACEMENT THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. C1-INH REPLACEMENT THERAPY MARKET: RESEARCHAI
FIGURE 26. C1-INH REPLACEMENT THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 27. C1-INH REPLACEMENT THERAPY MARKET: RESEARCHCONTACTS
FIGURE 28. C1-INH REPLACEMENT THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. C1-INH REPLACEMENT THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY NANOFILTERED C1-INH, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PASTEURIZED C1-INH, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RECOMBINANT C1-INH, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SHORT TERM PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOMECARE SETTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 88. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 89. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 90. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 91. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 94. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 95. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. CANADA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 104. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 105. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 108. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 109. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. MEXICO C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 176. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 177. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 180. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 181. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. GERMANY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 190. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 191. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 194. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 195. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. FRANCE C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 218. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 219. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 222. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 223. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. ITALY C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 230. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 231. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 232. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 233. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 236. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 237. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SPAIN C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 286. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 287. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 288. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 289. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 292. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 293. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. DENMARK C1-INH REPLACEMENT THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 300. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 301. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2018-2024 (USD MILLION)
TABLE 302. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PLASMA DERIVED C1-INH, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS C1-INH REPLACEMENT THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this C1-INH Replacement Therapy market report include:
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Pharming Group N.V.
  • Swedish Orphan Biovitrum AB
  • Kedrion S.p.A.
  • LFB S.A.

Related Reports

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Plasma Protease C1-Inhibitor Treatment Market by Drug Type, by Dosage, by Distribution Channel, and by Region - Product Image

Plasma Protease C1-Inhibitor Treatment Market by Drug Type, by Dosage, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Complement C1 Inhibitors - Pipeline Insight, 2025 - Product Image

Complement C1 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Ruconest Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Ruconest Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Hereditary Angioedema Market Report 2025 - Product Image

Hereditary Angioedema Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.